City Therapeutics, Inc. Common Stock Net Assets

Latest as of June 2026: $-131.72 Million USD

City Therapeutics, Inc. Common Stock net assets. Based on the latest financial reports, City Therapeutics, Inc. Common Stock (CTY) has net assets worth $-131.72 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($208.61 Million) and total liabilities ($340.33 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of City Therapeutics, Inc. Common Stock to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets $-131.72 Million
% of Total Assets -63.14%
Annual Growth Rate N/A
5-Year Change -100.91%
10-Year Change -103.09%
Growth Volatility 3779.5

Net Assets of City Therapeutics, Inc. Common Stock (2005–2025)

Net assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. This chart illustrates how City Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of City Therapeutics, Inc. Common Stock to measure how much of total assets are equity-financed.

Annual Net Assets for City Therapeutics, Inc. Common Stock (2005–2025)

The table below shows the annual net assets of City Therapeutics, Inc. Common Stock from 2005 to 2025. For live market cap and overall valuation, see City Therapeutics, Inc. Common Stock market cap and net worth.

Year Net Assets Change
2025-12-31 $-84.66 Million -187.70%
2024-12-31 $-29.43 Million -100.29%
2019-12-31 $10.12 Billion +2.52%
2018-12-31 $9.87 Billion +5.69%
2017-12-31 $9.34 Billion +7.42%
2016-12-31 $8.69 Billion -2.41%
2015-12-31 $8.91 Billion -3.01%
2014-12-31 $9.18 Billion +281.83%
2013-12-31 $2.40 Billion -12.32%
2012-12-31 $2.74 Billion +16.97%
2011-12-31 $2.35 Billion +116.40%
2010-12-31 $-14.30 Billion -5.42%
2009-12-31 $-13.56 Billion +5.50%
2008-12-31 $-14.35 Billion -4.59%
2007-12-31 $-13.72 Billion -12572.73%
2006-12-31 $110.00 Million +100.68%
2005-12-31 $-16.07 Billion --

Equity Component Analysis

This analysis shows how different components contribute to City Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 8910400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

City Therapeutics, Inc. Common Stock Net Assets Breakdown (December 2025)

City Therapeutics, Inc. Common Stock net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Other Components $4.45 Million %
Total Equity $-84.66 Million 100.00%

City Therapeutics, Inc. Common Stock Competitors by Market Cap

The table below lists competitors of City Therapeutics, Inc. Common Stock ranked by their market capitalization.

Company Market Cap
Daily Journal Corp
NASDAQ:DJCO
$911.21 Million
Amerigo Resources Ltd.
TO:ARG
$911.28 Million
BrightView Holdings
NYSE:BV
$912.11 Million
Foshan Electrical and Lighting Co Ltd
SHE:000541
$912.30 Million
Ningbo Sunrise Elc Technology Co Ltd Class A
SHE:002937
$910.97 Million
SpartanNash Co
NASDAQ:SPTN
$910.90 Million
Hunan New Wellful Co Ltd
SHG:600975
$910.67 Million
ATEX Resources Inc.
V:ATX
$910.56 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in City Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -29,425,000 to -84,655,000, a change of -55,230,000.
  • Net loss of 58,505,000 reduced equity.
  • Other factors increased equity by 3,275,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-58.51 Million -69.11%
Other Changes $3.27 Million +3.87%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares City Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2024-12-31 $-0.61 $18.10 x
2025-12-31 $-1.75 $18.10 x

Capital Efficiency Dashboard

This dashboard shows how efficiently City Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -431.39%
  • • Asset Turnover: 0.09x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is below the historical average (55.44%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 41.82% 9.72% 0.00x -0.36x $743.40 Million
2006 69.54% 12.19% 0.66x 8.58x $1.03 Billion
2007 152.71% 15.11% 14.11x 0.72x $1.39 Billion
2008 182.95% 13.84% 33.84x 0.39x $1.36 Billion
2009 383.65% 12.30% 8.35x 3.73x $1.17 Billion
2010 0.00% 11.67% 41.95x 0.00x $1.17 Billion
2011 5.49% 8.18% 0.38x 1.76x $-445.70 Million
2012 8.51% 9.60% 0.53x 1.68x $-148.40 Million
2013 10.03% 11.01% 0.55x 1.67x $2.70 Million
2014 10.56% 10.98% 0.39x 2.45x $51.70 Million
2015 12.06% 11.98% 0.42x 2.41x $183.30 Million
2016 12.48% 12.18% 0.42x 2.43x $215.80 Million
2017 17.75% 19.38% 0.41x 2.24x $723.30 Million
2018 16.87% 19.60% 0.41x 2.09x $678.20 Million
2019 18.06% 22.40% 0.39x 2.08x $815.30 Million
2024 0.00% -1002.02% 0.02x 0.00x $-24.89 Million
2025 0.00% -431.39% 0.09x 0.00x $-50.04 Million

Industry Comparison

This section compares City Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $230,249,706
  • Average return on equity (ROE) among peers: -88.16%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
City Therapeutics, Inc. Common Stock (CTY) $-131.72 Million 41.82% N/A $911.01 Million
Aardvark Therapeutics, Inc. Common Stock (AARD) $-27.92 Million 0.00% 0.00x $28.96 Million
Abcellera Biologics Inc (ABCL) $1.23 Billion 12.85% 0.25x $3.75 Billion
Abeona Therapeutics Inc (ABEO) $134.04 Million -42.28% 0.30x $138.39 Million
Acumen Pharmaceuticals Inc (ABOS) $188.78 Million -22.70% 0.04x $15.46 Million
Abpro Holdings, Inc. (ABP) $3.07 Million -479.81% 1.57x $2.00 Million
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $1.41 Billion
Arbutus Biopharma Corp (ABUS) $45.35 Million -59.09% 0.17x $810.25 Million
ABVC Biopharma Inc (ABVC) $13.30 Million -59.47% 0.58x $24.26 Million
Abivax SA American Depositary Shares (ABVX) $18.59 Million -164.77% 1.78x $7.50 Billion
ACADIA Pharmaceuticals Inc (ACAD) $627.01 Million -44.91% 0.25x $3.23 Billion

About City Therapeutics, Inc. Common Stock

NASDAQ:CTY USA Biotechnology
Market Cap
$911.01 Million
Market Cap Rank
#9050 Global
#2589 in USA
Share Price
$18.10
Change (1 day)
-4.64%
52-Week Range
$16.41 - $22.14
All Time High
$22.14
About

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more